Source: The Next Web
ByteDance's recommendation engine—built to maximize engagement through behavioral prediction—is now being applied to protein folding and molecular targeting, two problems where traditional pharma has repeatedly failed. The shift shows that sequence prediction at scale (whether video preference or amino acid structure) is a learnable skill, and that deep learning talent developed in consumer tech has direct utility in biology where the stakes are patient outcomes rather than watch time. If this team successfully targets proteins that existing drug discovery has abandoned as intractable, AI-native companies could operate as infrastructure providers in healthcare, competing directly with pharma's discovery capabilities and talent recruitment.